Glycopyrrolate Patent Expiration
Glycopyrrolate is Used for managing chronic obstructive pulmonary disease (COPD) through maintenance treatment of airflow obstruction. It was first introduced by Casper Pharma Llc
Glycopyrrolate Patents
Given below is the list of patents protecting Glycopyrrolate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lonhala Magnair Kit | US10744277 | Aerosol delivery device and method of operating the aerosol delivery device | Dec 07, 2036 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US10688518 | Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator | Nov 12, 2036 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US10376661 | Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element | Sep 14, 2035 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US9604018 | Aerosol therapy device | May 16, 2033 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US9168556 | Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer | Sep 01, 2032 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US9789270 | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized | Oct 30, 2030 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US10940110 | Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations | Feb 26, 2029 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US9265900 | Disposable ampoule for an aerosol generating device | Dec 07, 2028 | Sumitomo Pharma Am |
| Seebri Neohaler | US8182838 | Dry powder composition comprising co-jet milled particles for pulmonary inhalation | Oct 20, 2028 | Novartis |
| Seebri Neohaler | US8479730 | Inhaler device | Oct 11, 2028 | Novartis |
| Lonhala Magnair Kit | US11278683 | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
Aug 16, 2026
(Expired) | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US7931212 | Fluid droplet production apparatus and method |
Nov 25, 2025
(Expired) | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US7458372 | Inhalation therapy device |
Nov 18, 2024
(Expired) | Sumitomo Pharma Am |
| Robinul | US7091236 | Method for increasing the bioavailability of glycopyrrolate |
Apr 24, 2024
(Expired) | Casper Pharma Llc |
| Robinul Forte | US7091236 | Method for increasing the bioavailability of glycopyrrolate |
Apr 24, 2024
(Expired) | Casper Pharma Llc |
| Lonhala Magnair Kit | US8511581 | Fluid droplet production apparatus and method |
Nov 08, 2023
(Expired) | Sumitomo Pharma Am |
| Cuvposa | US7638552 | Method for increasing the bioavailability of glycopyrrolate |
Aug 20, 2023
(Expired) | Merz Pharms |
| Cuvposa | US7816396 | Method for increasing the bioavailability of glycopyrrolate |
Aug 20, 2023
(Expired) | Merz Pharms |
| Lonhala Magnair Kit | US7316067 | Forming a perforate membrane by laser drilling and a subsequent electro-polishing step |
Sep 06, 2022
(Expired) | Sumitomo Pharma Am |
| Seebri Neohaler | US7736670 | Method of making particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Seebri Neohaler | US8048451 | Pharmaceutical compositions for inhalation |
Jun 27, 2021
(Expired) | Novartis |
| Seebri Neohaler | US8303991 | Method of making particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Seebri Neohaler | US8435567 | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation |
Jun 27, 2021
(Expired) | Novartis |
| Seebri Neohaler | US8580306 | Particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Seebri Neohaler | US8956661 | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof |
Jun 27, 2021
(Expired) | Novartis |
| Seebri Neohaler | US9931304 | Method of making particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Seebri Neohaler | US9962338 | Method of making particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Seebri Neohaler | US7229607 | Treatment of respiratory disease |
Apr 09, 2021
(Expired) | Novartis |
| Seebri Neohaler | US8029768 | Treatment of respiratory diseases |
Apr 09, 2021
(Expired) | Novartis |
| Lonhala Magnair Kit | US6962151 | Inhalation nebulizer |
Oct 27, 2020
(Expired) | Sumitomo Pharma Am |
| Seebri Neohaler | US6528678 | Phosgene-free process for preparing carbamates |
Apr 24, 2018
(Expired) | Novartis |
| Seebri Neohaler | US6582678 | Carrier particles for use in dry powder inhalers |
Apr 24, 2018
(Expired) | Novartis |
| Seebri Neohaler | US6521260 | Carrier particles for use in dry powder inhalers |
Jan 31, 2016
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Glycopyrrolate's patents.
Latest Legal Activities on Glycopyrrolate's Patents
Given below is the list recent legal activities going on the following patents of Glycopyrrolate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent | 15 Dec, 2025 | US8580306 |
| Maintenance Fee Reminder Mailed | 30 Jun, 2025 | US8580306 |
| Expire Patent | 09 Jun, 2025 | US8435567 |
| Maintenance Fee Reminder Mailed | 23 Dec, 2024 | US8435567 |
| Expire Patent | 09 Dec, 2024 | US8303991(Litigated) |
| Maintenance Fee Reminder Mailed Critical
| 24 Jun, 2024 | US8303991(Litigated) |
| Expire Patent Critical
| 04 Dec, 2023 | US8048451 |
| Maintenance Fee Reminder Mailed Critical
| 19 Jun, 2023 | US8048451 |
| Expire Patent Critical
| 27 Mar, 2023 | US8956661 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Mar, 2023 | US8029768 |
About Veterinary Glycopyrrolate
Glycopyrrolate is used in drugs marketed by 2 different companies: Cronus Pharma Specialities India Private Ltd, Zoetis Inc.
Other drugs containing Glycopyrrolate are: Glycopyrrolate injectable, robinul v , Robinul v injectable .
Glycopyrrolate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Glycopyrrolate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients | AeroRx Therapeutics Inc. | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction | MeiraGTx, LLC | NA |
COMPLETED
(Aug 1, 2026)
| PHASE1 |